On July 25, shares of GC Green Cross Wellbeing (234690.KQ) rocketed 19.16% to close at 14,680 won, fueled by the announcement of its new human tissue-based extracellular matrix (ECM) skin booster, Giselle Rebonne. This leap underscores surging investor confidence in regenerative aesthetics, a fast-growing sector blending advanced biotech with beauty demands.
Innovative Edge of Giselle Rebonne
Giselle Rebonne stands out as a next-generation skin booster derived from human acellular dermal matrix (hADM), delivering the ECM structure directly to skin layers. Unlike traditional boosters that merely stimulate collagen indirectly, this product provides a scaffold for true tissue remodeling, promoting structural regeneration over superficial fixes.
- Human tissue origin enhances biocompatibility and natural integration.
- Proprietary decellularization removes cells and immune triggers, slashing rejection risks.
- Ideal for addressing aging signs like loss of elasticity and volume through foundational repair.
Production and Supply Chain Strength
GC Green Cross Wellbeing partners with MS Bio for tissue processing, while managing raw materials via its Eumseong tissue bank. This vertical integration ensures quality control in a market wary of synthetic alternatives. The result is a product poised for minimal inflammation and superior outcomes, aligning with rising consumer preference for bio-identical treatments.
Portfolio Growth Amid Competitive Landscape
This launch bolsters GC Green Cross Wellbeing's aesthetics lineup, now spanning Laennec placenta injections, dermal fillers, skin boosters, and Innovo botulinum toxin. It mirrors strategies by rivals like Hugel, co-promoting with Hans Biomed's Cellrderm, and CG Bio's planned ECM booster bundled with Daewoong's Nabota. As global demand for non-invasive, regenerative skincare hits billions annually—driven by aging populations and social media-fueled beauty standards—such innovations signal a shift toward sustainable, biology-mimicking solutions, potentially reshaping South Korea's dominance in med-aesthetics exports.
